L-carnosine in Schizophrenia

Efficacy of L-carnosine as an add on treatment for negative and cognitive symptoms in schizophrenia - A randomized double blind placebo controlled study - LCARS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017646

Enrollment

100

Registered

2019-02-13

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20- Schizophrenia

Interventions

Intervention1: L-Carnosine: 400-800 mg BD ,oral for 6 months Control Intervention1: placebo: placebo for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged 18-40 years. 2.ICD -10 diagnosis of schizophrenia. 3.Willing to participate in the study 4.Education 9th std and above 5.Cognitive deficit of 15% on one domain of NIMHANS battery. 6.SANS total score > 60

Exclusion criteria

Exclusion criteria: 1.Patients who are uncooperative due to the severity of the illness. 2.Existence of serious medical/neurological disorder, known allergic to L-carnosine. 3.Patients with mental retardation, H/O drug or alcohol dependence. 4.Women who were currently pregnant /breastfeeding. 5.Not consenting to participate in the study.

Design outcomes

Primary

Measure	Time frame
Improvement in negative symptoms and functioning in patients suffering from schizophrenia.Timepoint: 18 months	—

Secondary

Measure	Time frame
improvement in cognitive symptomsTimepoint: 18 months	—

Countries

India

Contacts

Public ContactSindhu Maran

Schizophrenia Research Foundation

hematharoor@scarfindia.org04426151073

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026